Published in Am J Med on July 23, 2010
Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med (2014) 3.63
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
Cost of dabigatran for atrial fibrillation. BMJ (2011) 0.94
Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study. Eur J Clin Pharmacol (2012) 0.89
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract (2013) 0.81
Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation - a cohort study from Sweden using propensity score analyses. Diabetol Metab Syndr (2014) 0.80
Neighbourhood socio-economic status and all-cause mortality in adults with atrial fibrillation: A cohort study of patients treated in primary care in Sweden. Int J Cardiol (2015) 0.79
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. Pharmaceuticals (Basel) (2012) 0.78
Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77
Warfarin treatment and risk of myocardial infarction - A cohort study of patients with atrial fibrillation treated in primary health care. Int J Cardiol (2016) 0.75
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions. Thrombosis (2012) 0.75
Anticoagulation in Atrial Fibrillation. Arrhythm Electrophysiol Rev (2012) 0.75
Dabigatran and myocardial infarction: a foggy scenario. Vasc Health Risk Manag (2014) 0.75
A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Curr Emerg Hosp Med Rep (2016) 0.75
Acute myocardial infarction after switching from warfarin to dabigatran. Oman Med J (2015) 0.75
Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. Sci Rep (2017) 0.75
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest (2012) 2.33
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22
Atrial fibrillation. Lancet (2011) 2.05
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. J Hypertens (2012) 1.51
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". Thromb Haemost (2009) 1.40
Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol (2010) 1.28
Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol (2011) 1.27
Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One (2013) 1.09
Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost (2009) 1.04
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev (2013) 1.03
Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2012) 1.00
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J (2013) 0.97
Stroke and thromboembolism in atrial fibrillation. Circ J (2012) 0.95
Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med (2012) 0.94
Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol (2012) 0.93
Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol (2014) 0.92
Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol (2012) 0.91
Recruitment of ethnic minority patients to a cardiac rehabilitation trial: the Birmingham Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263]. BMC Med Res Methodol (2005) 0.89
Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can J Cardiol (2013) 0.88
Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens (2007) 0.88
Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost (2010) 0.88
Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more). Clin Cardiol (2014) 0.87
Patients' and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns (2012) 0.86
Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail (2012) 0.85
Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke (2007) 0.85
TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord (2010) 0.84
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost (2012) 0.84
Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. Clin Res Cardiol (2011) 0.84
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost (2012) 0.83
Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. Circulation (2013) 0.82
The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. J Am Coll Cardiol (2012) 0.82
Modern management of atrial fibrillation requires initial identification of "low-risk" patients using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction. Circ J (2014) 0.81
Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost (2016) 0.80
Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation. Eur J Clin Invest (2013) 0.80
Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens (2011) 0.80
Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint. Europace (2010) 0.79
An epidemic of atrial fibrillation? Europace (2011) 0.79
Maintaining therapeutic anticoagulation: the importance of keeping "within range". Chest (2007) 0.79
Best practice for atrial fibrillation patient education. Curr Pharm Des (2015) 0.79
Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail (2012) 0.79
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. Chest (2013) 0.79
Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurol (2010) 0.79
Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb Haemost (2009) 0.78
The assessment of stroke and bleeding risk in atrial fibrillation: where are we now? Expert Rev Cardiovasc Ther (2010) 0.78
Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. Ann Med (2009) 0.78
Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. Am J Med (2009) 0.78
Circulating endothelial cells, arterial stiffness, and cardiovascular risk stratification in hypertension. Chest (2007) 0.78
Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. J Thromb Thrombolysis (2006) 0.77
Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly. Circ J (2013) 0.77
Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing (2011) 0.77
Alcohol intake and prognosis of atrial fibrillation. Heart (2013) 0.77
The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest (2014) 0.77
Atrial fibrillation and mortality: the impact of antithrombotic therapy. Eur Heart J (2010) 0.77
Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis (2009) 0.76
Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age Ageing (2010) 0.76
Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. Thromb Haemost (2014) 0.76
Reply: To PMID 22858389. J Am Coll Cardiol (2013) 0.75
Can we IMPROVE bleeding risk assessment for acutely ill, hospitalized medical patients? Chest (2011) 0.75
Anticoagulation for atrial fibrillation patients with CHADS score of 1. J Cardiovasc Electrophysiol (2010) 0.75
Combination anticoagulant and antiplatelet therapy in atrial fibrillation patients. Rev Esp Cardiol (2009) 0.75
Anticoagulation control with vitamin K antagonists: how well are we doing? Chest (2006) 0.75
Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. Hypertens Res (2013) 0.75
Atrial fibrillation (chronic). BMJ Clin Evid (2008) 0.75
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost (2008) 0.75
The quest for new anticoagulants: from clinical development to clinical practice. Cardiovasc Ther (2010) 0.75
To the Editor - Adding renal dysfunction to CHA₂DS₂-VASc improves stroke prediction postcatheter ablation. Heart Rhythm (2012) 0.75
Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves. Chest (2009) 0.75
Bleeding risk during oral anticoagulation therapy for atrial fibrillation. Europace (2013) 0.75
Vital exhaustion and cardiovascular disease: are circulating fibrinogen and D-dimer levels a plausible link? Stress (2008) 0.75
Challenges facing anticoagulation among the elderly and frail. Age Ageing (2009) 0.75
The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation. Ann Intern Med (2016) 0.75
Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. Curr Med Chem (2016) 0.75
Soluble Fas and Fas ligand in pregnancy: influence of hypertension. Angiology (2011) 0.75
The first prognostic model for stroke and death in patients with systolic heart failure. J Cardiol (2015) 0.75
Angiogenin and hemoxygenase in pregnancy: influence of hypertension. Angiology (2011) 0.75
Oral anticoagulants for stroke prevention in atrial fibrillation. Curr Probl Cardiol (2014) 0.75
Atrial fibrillation: Anticoagulation for AF: can we GRASP-AF patients? Nat Rev Cardiol (2013) 0.75
Stroke prevention in atrial fibrillation patients. Expert Opin Pharmacother (2010) 0.75
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J (2020) 0.75
Adolescents' and Young Adults' Lived Experiences Following Venous Thromboembolism: "It will always lie in wait". Nurs Res (2016) 0.75
Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. Expert Rev Cardiovasc Ther (2013) 0.75